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Background: Both adaptive servoventilation (ASV) and
nocturnal oxygen therapy improve sleep disordered
breathing (SDB), but their effects on cardiac
parameters have not been compared systematically.
Methods and results: 43 patients with chronic heart
failure (CHF; left ventricular ejection fraction (LVEF)
≤50%) with SDB were randomly assigned to undergo
ASV (n=19, apnoea hypopnoea index (AHI)=34.2±12.1/h)
or oxygen therapy (n=24, 36.9±9.9/h) for 3 months. More
than 70% of SDB events in both groups were central
apnoeas or hypopnoeas. Although nightly adherence was
less for the ASV group than for the oxygen group (4.4
±2.0 vs 6.2±1.8 h/day, p<0.01), the improvement in AHI
was larger in the ASV group than in the oxygen group
(−27.0±11.5 vs −16.5±10.2/h, p<0.01). The N-terminal
pro-brain natriuretic peptide (NT-proBNP) level in the ASV
group improved significantly after titration (1535±2224 to
1251±2003 pg/mL, p=0.01), but increased slightly at
follow-up and this improvement was not sustained
(1311±1592 pg/mL, p=0.08). Meanwhile, the level of
plasma NT-proBNP in the oxygen group did not show a
significant change throughout the study (baseline 1071
±1887, titration 980±1913, follow-up 1101±1888 pg/mL,
p=0.19). The significant difference in the changes in the
NT-proBNP level throughout the study between the 2
groups was not found (p=0.30). Neither group showed
significant changes in echocardiographic parameters.
Conclusions: Although ASV produced better resolution
of SDB in patients with CHF as compared with oxygen
therapy, neither treatment produced a significant
improvement in cardiac function in the short term.
Although we could not draw a definite conclusion
because of the small number of participants, our data do
not seem to support the routine use of ASV or oxygen
therapy to improve cardiac function in patients with CHF
with SDB.
Trial registration number NCT01187823 (http://www.
clinicaltrials.gov).
INTRODUCTION
Sleep disordered breathing (SDB) is an inde-
pendent risk for mortality among patients
with chronic heart failure (CHF)1–4 and the
clinical effects of several SDB treatment
modalities, such as continuous positive
airway pressure (CPAP) and adaptive servo-
ventilation (ASV), have been investigated.5–8
Two previous randomised controlled trial
(RCT) studies reported that ASV improved
SDB and cardiac function more effectively
than did CPAP.9 10 In one of those trials, ASV
showed better nightly adherence than CPAP,
which was considered to be one of the
reasons for the superior effects of ASV over
CPAP. However, a recent large RCT showed
that all-cause and cardiovascular mortality
were both increased with ASV therapy.11
Thus, the effects of ASV for patients with
CHF with SDB remain controversial.
On the other hand, although nocturnal
oxygen therapy also decreases the severity of
SDB in patients with CHF,12 the beneﬁts of
oxygen therapy on cardiac function have
KEY QUESTIONS
What is already known about this subject?
▸ The benefits of treatment of sleep disordered
breathing (SDB) for cardiac function in patients
with chronic heart failure (CHF) remain
controversial.
What does this study add?
▸ This clinical randomised trial compared the
effects of adaptive servoventilation (ASV) and
nocturnal oxygen therapy on patients with CHF
with SDB. While ASV produced better resolution
of SDB in patients with CHF as compared with
oxygen therapy, neither treatment could produce
a significant improvement in cardiac function.
How might this impact on clinical practice?
▸ Our data did not support routine use of ASV or
oxygen therapy to improve cardiac function in
patients with CHF with SDB.
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rarely been compared with those of ASV. Teschler et al13
showed that the effect of ASV on the apnoea hypopnoea
index (AHI) was superior to that of oxygen therapy, but
the two treatment modalities had similar effects on hyp-
oxaemia during sleep. Since SDB is thought to be detri-
mental to patients with CHF, mainly because of
hypoxaemia, it is possible that oxygen therapy produces
positive effects on cardiac function similar to ASV.14 15
Further, oxygen therapy showed quite good compliance
(7–8 h/night) in patients with CHF.16 Although
Campbell et al17 compared the effects of ASV and
oxygen therapy on central sleep apnoea in seven
patients with CHF, a trial with a larger sample size is war-
ranted. We therefore hypothesised that the suboptimal
effect of oxygen therapy on SDB might be counterba-
lanced by better adherence as compared with ASV,
resulting in similar effects of both treatments on cardiac
function. We thus performed an RCT to compare the
clinical effects of these two modalities in patients with
CHF. In addition, since body ﬂuid balance and body
composition are associated with the pathophysiology of
both SDB and CHF,18–20 we also investigated whether
SDB treatments affect these variables.
METHODS
Patients screening
Candidates with CHF for participation in the trial were
consecutively screened in Kyoto University Hospital on
the basis of the following criteria: (1) age 20–80 years;
(2) CHF deﬁned as LVEF of ≤50% on echocardiog-
raphy; (3) AHI of ≥20/h with more than 15% of respira-
tory events being central; and (4) receiving a maximal
cardiac medication regimen. The exclusion criteria were
(1) any changes to cardioactive drug prescriptions,
including diuretics in the prior 6 weeks; (2) admission
for deterioration of heart failure or ischaemic heart dis-
eases in the prior 6 weeks; (3) previous use of CPAP,
ASV or nocturnal oxygen therapy for SDB; (4) being on
renal dialysis; (5) history of stroke with neurological
deﬁcit; and (6) clinically unstable CHF judged by the
attending cardiologists. First, potential candidates were
consecutively screened from the heart failure clinic and
they were invited to undergo screening for SDB by
in-laboratory polysomnography (PSG). We invited
patients both with and without CHF symptoms. Those
whose PSG ﬁndings fulﬁlled the above criteria pro-
ceeded to the randomisation. This study was approved
by the Ethics Committee of the study institute, and
written informed consent was obtained from all patients.
This trial was registered at http://www.clinicaltrials.gov
(NCT01187823).
Sleep study
Diagnosis of SDB was conﬁrmed by PSG (SomnoStar
pro, Cardinal Health, Dublin, Ohio, USA; or Alice 4,
Philips Respironics, Murrysville, Pennsylvania, USA).
Surface electrodes were attached using standard
techniques to obtain an electro-oculogram, electromyo-
gram of the chin and a 12-lead EEG. Sleep stages were
deﬁned according to the criteria of Rechtschaffen and
Kales.21 Respiratory efforts were monitored by calibrated
respiratory inductive plethysmography. Airﬂow was moni-
tored by a nasal pressure transducer and supplemented
by an oronasal thermal sensor. Arterial oxygen satur-
ation (SpO2) was monitored continuously with a pulse
oximeter. According to the previous study, central sleep
apnoea was deﬁned as the absence of tidal volume for
10 s or more without thoracoabdominal motion, and
central hypopnoea was deﬁned as a reduction of 50% or
more in tidal volume from baseline for 10 s or more
without airﬂow limitation, as detected by the measure-
ment of nasal pressure.5 Apnoea and hypopnoea were
categorised as obstructive if there was out-of-phase
motion of the rib cage and abdomen, or if airﬂow limi-
tation was present. Respiratory events with both central
and obstructive components were categorised as
obstructive. AHI values were expressed as the number of
episodes of apnoea and hypopnoea per hour over the
total sleep time. The 3% oxygen desaturation index
(ODI) was deﬁned as the number of desaturations of
3% or more per hour of sleep. The length of time that
SpO2 was less than 90% during sleep was also calculated
for each patient. The analysis of each sleep study was
performed in a blinded manner by four experienced
sleep technicians.
Randomisation, intervention and follow-up
Eligible patients were randomly assigned to the ASV or
oxygen therapy group and then admitted for two nights
for treatment titration. The randomisation was con-
ducted by the data-coordinating centre in a blind
manner, stratifying for two factors (age: >66 or
≤66 years; LVEF: >40% or ≤40%). The attending physi-
cians and patients were not blind to the study treatment.
The ASV instrument (BiPAP autoSV Advanced, Philips
Respironics) used in the present study was able to adjust
both pressure support (PS) and expiratory positive
airway pressure (EPAP) automatically within the prede-
termined range.22 During the ﬁrst night of titration,
minimum and maximum EPAPs were determined
mainly to abolish obstructive respiratory events. During
the second night, the minimum PS was set to 0 cm H2O
and the maximum PS to 12 cm H2O (or not higher than
the maximum that the patient could tolerate) to opti-
mally abolish central respiratory events. The mandatory
breath rate was set as an automatic or ﬁxed rate of >10
breaths/min.
For patients allocated to oxygen therapy, during the
second PSG, the oxygen rate was adjusted to remain in
the range of 2–4L/min to keep patients’ SpO2 level at
95–99% for as long as possible to prevent both
hypo-oxaemia and hyperoxaemia. After the second PSG
was complete, the amount of O2 delivered during the
following treatment period was determined in each case.
After the treatment titration, patients were instructed to
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use the allocated treatment at home as much as
possible.
Three months after the titration, patients underwent a
third sleep study to evaluate the effect of the treatments.
We also recorded the usage time of the ASV device or




The primary outcome was change in LVEF.
Echocardiography was performed at baseline and at
follow-up by a single experienced echocardiographer
who was blind to the patient’s treatment allocation.
LVEF was calculated using a modiﬁed Simpson’s
method. At the same time, 6 min walking distance and
quality of life (QoL), as measured by the Minnesota
Living with Heart Failure Questionnaire (MLHFQ), were
also quantiﬁed.
Blood samples were drawn in the morning following
PSG. The level of plasma N-terminal pro-brain natri-
uretic peptide (NT-proBNP) was measured at baseline,
following the titration and after the 3-month PSG.
Body fluid balance and body composition
Anthropometric parameters, blood pressure (BP) and
body composition were measured in the morning follow-
ing PSG. The body composition of each participant was
examined by using a bioelectrical impedance analysis
(BIA) instrument (Inbody s20, BIOSPACE, Seoul, South
Korea) at baseline and at follow-up. This is a multifre-
quency impedance plethysmograph body composition
analyser, which takes readings from the body using eight-
point tactile electrodes. The detailed principles of meas-
urement of this device are provided in the online sup-
plementary data. By adopting the proprietary
algorithms, the amount of total body water (TBW),
extracellular water (ECW), body fat mass and lean body
fat mass were recorded. On the basis of a previous
study,23 the ratio of ECW to TBW as a surrogate for ﬂuid
overload was also calculated. According to the manufac-
turer’s guidelines, these measurements were not per-
formed in seven participants (four ASV and three
oxygen group) with implanted electrical devices.
Sample size and statistical analysis
According to the previous studies examining the effects of
intervention for SDB on cardiac function,12 a change in
Figure 1 Trial design. ASV, adaptive servo ventilation.
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LVEF (ie, ≥4%) between the two groups was determined
to indicate a clinically relevant difference. It was calculated
that 17 patients per group would be needed to detect this
difference with an SD of 4.0, an α value of 0.05 and 80%
power using two-sided signiﬁcance testing. The efﬁcacy
analyses were performed on the full analysis set (FAS),
which included all patients who used the allocated therapy
for at least one night at home. Missing values for the
outcome analysis were input by adopting the procedure of
last observation carried forward procedure. The per-
protocol analysis set (PPAS), which included only patients
who completed the study course, was also analysed.
Background data and changes in parameters during
the study course were compared between the two groups
using the unpaired t test or Mann-Whitney U test for
continuous variables. The χ2 test or Fisher’s exact test
was used to compare categorical variables. The paired t
test and Wilcoxon signed rank test were used to evaluate
the changes in parameters within the same group.
Repeated measure analyses of variance with post hoc
pairwise comparison were used to compare the changes
in AHI, 3% ODI and log-transformed NT-proBNP level
within the same group and between two groups. A two-
tailed p value of <0.05 was considered statistically signiﬁ-
cant. All statistical analyses were performed using JMP
V.11 (SAS Institute Inc, Cary, North Carolina, USA) and
R software (http://www.r-project.org/).
RESULTS
The ﬂow of patients through the trial is shown in
ﬁgure 1. Eighty-seven patients were screened, and 43
patients were randomised to receive ASV (n=19) or
oxygen therapy (n=24). The imbalance in the total
number happened because of the imbalance in each
strata by chance. Twenty-one patients in the oxygen
group and all 19 in the ASV group used the allocated
treatment for at least one night and were included in
the FAS. Three patients in the oxygen group were
excluded from the FAS: two of them withdrew their
consent, and one was admitted owing to deteriorated
heart failure before the start of the allocated treatment.
Among 40 patients in the FAS, 18 patients in the oxygen
group and 15 in the ASV group completed the study
protocol and were included in the PPAS. Although the
number of patients in the PPAS did not reach the goal,
we had to stop recruiting patients because of ﬁnancial
constraints. Patients with primary valvular heart disease
were not enrolled. No changes were made to the pre-
scriptions of patients in the PPAS during the course of
the study.
The background data of the FAS at baseline are shown
in table 1. Although body mass index (BMI) was signiﬁ-
cantly lower in the ASV group than in the oxygen
group, no other differences in these variables were
found between the two groups. The detailed data for
the echocardiographic and PSG parameters at baseline
are shown in table 2 and online supplementary table S1,
respectively.
Both ASV and oxygen therapy decreased AHI signiﬁ-
cantly (ASV: baseline 34.2±12.1, titration 10.0±10.2,
follow-up 7.2±5.9/h, p<0.01; oxygen: baseline 36.9±9.9,
titration 19.5±11.0, follow-up 19.4±8.4/h, p<0.01).
However, the improvement in AHI was signiﬁcantly
Table 1 Clinical background of study participants: full analysis set
ASV (n=19) Oxygen (n=21) p Value
Male, n (%) 17 (89.4) 17 (81.0) 0.44
Age, years 68±9 69±9 0.91
Body mass index, kg/m2 22.9±2.9 24.7±2.4 0.04
NYHA classification (I/II/III), n 0/14/5 1/14/6 0.50
Main aetiology of heart failure
Old myocardial infarction, n (%) 10 (52.6) 10 (47.6)
Dilative cardiomyopathy, n (%) 9 (47.4) 9 (42.8)
Hypertrophic cardiomyopathy, n (%) 0 (0) 1 (4.8)
Sarcoidosis, n (%) 0 (0) 1 (4.8) 0.47
History of atrial fibrillation (%) 4 (21.1) 3 (14.3) 0.69
Medication
β-blocker, n (%) 14 (73.7) 18 (85.7) 0.44
Diuretics, n (%) 10 (52.6) 10 (47.6) 1.00
Ca-blocker, n (%) 3 (15.8) 3 (14.3) 1.00
ACE inhibitor/ARB, n (%) 13 (68.4) 17 (81.0) 0.47
Amiodarone, n (%) 2 (10.5) 1 (4.8) 0.60
Implanted biventricular pacemaker or cardiac defibrillator, n (%) 4 (21.1) 3 (14.3) 0.58
NT-proBNP, pg/mL 1200 (356–1720) 446 (195–1160.5) 0.10
Apnoea hypopnoea index, /h 34.2±12.1 36.9±9.9 0.45
Central/total apnoea hypopnoea index, per cent 83.1±15.7 73.1±26.2 0.16
3% oxygen desaturation index, /h 28.2±15.6 32.7±11.9 0.30
Values are expressed as mean±SD or median (first–third quartile).
ARB, angiotensin receptor blocker; ASV, adaptive servoventilation; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York
Heart Association.
4 Murase K, Ono K, Yoneda T, et al. Open Heart 2016;3:e000366. doi:10.1136/openhrt-2015-000366
Open Heart
greater in the ASV group than in the oxygen group
(p=0.01). Meanwhile, although both groups showed a
decrease in 3% ODI (ASV: baseline 28.2±15.6, titration
3.0±2.4, follow-up 3.9±4.1/h, p<0.01; oxygen: baseline
32.7±11.9, titration 3.3±5.6, follow-up 2.6±5.7/h, p<0.01),
the change in 3% ODI throughout the study did not
differ signiﬁcantly between the two groups (p=0.56)
(ﬁgure 2). ASV settings and the changes in other PSG
parameters in each group are shown in table 3 and
online supplementary table S1, respectively. For all
patients in the oxygen group, 3L/min of O2 was consid-
ered to be optimal for their SDB treatment and it was
administered to all of them for 3 months. The number
of hours of treatment usage was higher in the oxygen
group than in the ASV group (ASV 4.4±2.0 vs oxygen 6.2
±1.8 h/day, p<0.01; table 3).
With regard to cardiac function, neither group
showed a signiﬁcant change in LVEF and no signiﬁcant
difference in the changes in the echocardiographic
parameters was found between the two groups (table 2).
Systolic BP decreased signiﬁcantly in the ASV group,
whereas the MLHFQ score showed a decreasing trend in
both groups (table 4).
The level of plasma NT-proBNP in the oxygen group
did not show a signiﬁcant change throughout the study
(baseline 1071±1887, titration 980±1913, follow-up 1101
±1888 pg/mL, p=0.19). The NT-proBNP level in the ASV
group decreased signiﬁcantly after titration (1535±2224
to 1251±2003 pg/mL, p=0.01), but increased slightly at
follow-up and this improvement was not sustained (1311
±1592 pg/mL, p=0.08). A signiﬁcant difference in the
changes in the NT-proBNP level between the two groups
was not found (p=0.30; ﬁgure 3).
The ASV group showed a small but signiﬁcant increase
in body weight (61.3±12.6 to 62.4±12.6 kg, p=0.02).
From the BIA analysis in patients without an implanted
device, the amount of both ECW and TBW did not
change signiﬁcantly in either group, but the amount of
body fat increased in the ASV group (16.1±6.4 to 17.1
±6.2 kg, p=0.02; table 5).
Analyses of the PPAS are shown in the online supple-
mentary data (see online supplementary tables S2–6 and
ﬁgures S1 and 2). Overall, the results of the PPAS were
similar to those of the FAS except that the decrease in
LVEDV from baseline to follow-up was signiﬁcantly
greater in the ASV group than in the oxygen group
(−7.1±13.9 vs 12.6±31.4 mL, p=0.04; see online supple-
mentary table S3).
DISCUSSION
In the present trial for patients with CHFs with SDB,
although ASV showed greater improvement in AHI as
compared with oxygen therapy, neither of them led to
an improvement in the plasma NT-proBNP level or
LVEF after 3 months of treatment. Although previous
trials have reported conﬂicting results regarding the
effect of ASV or oxygen therapy on LVEF and plasma
NT-proBNP level,8 10 11 16 24 25 the reasons for these
inconsistent results remain to be elucidated.
As compared with cohorts in previous trials,9–11 24 25
the proportion of patients using cardiac medication
such as diuretics, ACE inhibitor and angiotensin recep-
tor blocker was smaller in the present cohort, even
though their LVEF scores and disease severity in terms
of New York Heart Association (NYHA) classiﬁcation
were similar. This suggests that this study included more
clinically stable patients with CHF as compared with pre-
vious studies. Therefore, it is possible that the effect of
SDB treatments on cardiac function might vary depend-
ing on subtle differences in the clinical condition of the
study population and on the severity of CHF. However,
Zhao et al26 and Sin et al27 reported a similar frequency
of cardiac medication use in their cohort with CHF;
thus, the rate of medication use among the present
cohort does not seem to differ substantially from that
among patients with CHF in the real world.
Investigations to identify the characteristics of patients
with CHF who may beneﬁt from the treatments of SDB
are warranted.
Further, the proportion of central SDB events was rela-
tively higher in the present cohort than in previous
ones.10 24 25 Another study has suggested that the BMI
of patients with CHF in Japan is lower than that in
Table 2 Echocardiographic parameters at baseline and
at 3 months follow-up: full analysis set
ASV (n=19) Oxygen (n=21) p* Value
Left ventricular ejection fraction, per cent
Baseline 35.2±10.0 36.0±10.3 0.80
3 months 35.6±11.8 37.0±11.4
△ 0.3±4.2 1.0±4.7 0.66
Left ventricular endo-diastolic diameter, mm
Baseline 58.9±9.3 60.3±7.9 0.61
3 months 58.7±9.1 60.0±9.5
△ −0.2±2.4 −0.3±2.8 0.85
Left ventricular endo-systolic diameter, mm
Baseline 48.8±10.6 50.9±10.3 0.54
3 months 48.4±11.2 50.1±12.5
△ −0.5±2.4 −0.8±3.7 0.77
Left ventricular endo-diastolic volume mL
Baseline 171.7±59.4 160.4±72.9 0.60
3 months 166.1±52.1† 171.2±84.9
△ −5.4±12.7 10.8±29.3 0.06
Left ventricular endo-systolic volume, mL
Baseline 112.3±57.2 108.9±70.2 0.87
3 months 110.5±51.7 114.4±75.2
△ −1.7±10.7 5.5±21.9 0.20
Left atrium diameter, mm
Baseline 43.9±6.6 46.5±8.5 0.29
3 months 44.8±6.3 46.8±7.7
△ 0.9±2.3 0.3±3.1 0.51
Values are expressed as mean±SD.
*p Value for comparison between the ASV and oxygen groups.
†p<0.10 versus baseline within the same group.
ASV, adaptive servoventilation.
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western countries.28 In fact, the participants’ BMI was
smaller in this study than in previous trials, and a higher
BMI has been reported to be a predictive factor for
obstructive sleep apnoea in patients with CHF.26 27
Therefore, this smaller BMI may be one of the reasons
for the smaller number of obstructive SDB events
observed in the present cohort as compared with previ-
ous ones. Since obstructive and central SDB events seem
to affect CHF pathophysiology in different ways, the
effect of SDB treatments on cardiac function can
change depending on the type of SDB event.29
Even though neither therapy could improve the
NT-proBNP level and LVEF, analysis of the PPAS
revealed that the decrease in LVEDV was greater in the
ASV group than in the oxygen group. In addition, the
ASV group showed a signiﬁcant decrease in the plasma
NT-proBNP level following titration, whereas the oxygen
group did not. These ﬁndings might be associated with
reverse remodelling and suggest that not just preventing
hypoxia but also normalising the breathing pattern
during sleep is beneﬁcial to decrease haemodynamic
stress in patients with CHF. Positive pressure with ASV
also might reduce left ventricular afterload by increasing
intrathoracic pressure and reducing left ventricular
transmural pressure in addition to reducing SDB
events.30 Further, the ASV group showed a small but sig-
niﬁcant increase in body weight, and in a large propor-
tion of cases, the increase was due to changes in body
fat mass. Since higher body fat mass is associated with a
better prognosis among patients with CHF,19 this change
might reﬂect a more favourable result in the ASV group
than in the oxygen group. However, whether the imple-
mentation of ASV generated these changes is uncertain,
and further studies investigating the effect of ASV on
metabolic factors such as energy expenditure and food
intake are warranted. Although these results seemed to
suggest favourable effects of ASV, further trials with
larger numbers of patients are required to establish
deﬁnitive clinical strategies.
Recently, a large RCT found that ASV did not improve
clinical outcomes among patients with CHF with
Figure 2 (A and B) Changes in the apnoea hypopnoea index (AHI) and 3% oxygen desaturation index (ODI) from baseline to
treatment titration and 3 months of therapy: full analysis set. Plotted line graphs indicate the mean±SE at each assessment.
*One-way repeated measure analyses of variance (ANOVA) showed that both adaptive servoventilation (ASV) and oxygen
therapy significantly decreased AHI (ASV: baseline 34.2±12.1, titration 10.0±10.2, follow-up 7.2±5.9/h, p<0.01; oxygen: baseline
36.9±9.9, titration 19.5±11.0, follow-up 19.4±8.4/h, p<0.01) and 3% ODI (ASV: baseline 28.2±15.6, titration 3.0±2.4, follow-up 3.9
±4.1/h, p<0.01; oxygen: baseline 32.7±11.9, titration 3.3±5.6, follow-up 2.6±5.7/h, p<0.01) within the same group. †Two-way
measured ANOVA showed that a significant difference was found in the changes in AHI (p=0.01) but not in 3% ODI (p=0.56)
throughout the study between the two groups.



















Hour of use, h/day 4.4±2.0 6.2±1.8 <0.01
Values are expressed as mean±SD.
ASV, adaptive servoventilation; EPAP, expiratory positive airway
pressure.
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predominantly central sleep apnoea.11 However, the
ASV device adopted in this study differed from that in
the large RCT. The algorithm for tracking patients’
breathing was different in the two studies. In addition,
the ASV device used in the large trial had ﬁxed EPAP
and more than 3 cm H2O of PS, whereas the device in
this study had auto-ﬂexible EPAP and its minimum PS
could be as low as 0 cm H2O. No previous study has
compared clinical effects between these ASV devices,
and the effects of ASV can vary depending on these con-
ditions. Another large, ongoing RCT (ClinicalTrials.gov
number, NCT01128816) is adopting the same ASV
device as in this study and will help both to interpret the
results of this study and to determine the clinical strat-
egy for treating SDB in patients with CHF.
Overall, even though ASV seemed to produce more
advantageous changes in SDB than oxygen therapy, these
changes were not associated with an improvement in
LVEF and NT-proBNP level in 3 months. Although we
cannot draw a deﬁnite conclusion because of the small
number of participants, our data did not seem to support
routine use of ASV or oxygen therapy to improve cardiac
function in patients with CHF with SDB. Further, in line
with a recent large RCT showing negative clinical effects
of ASV for patients with SDB,11 we cannot routinely rec-
ommend ASV use for this type of cohort unless further
studies ﬁrst clarify the mechanisms underlying the
Table 4 Cardiac parameters at baseline and after
3 months of therapy: full analysis set
ASV (n=19) Oxygen (n=21) p* Value
Systolic blood pressure, mm Hg
Baseline 121.5±19.2 120.5±15.4 0.86
3 months 116.3±16.3† 119.7±14.1
△ −5.2±10.7 −0.8±15.0 0.30
Diastolic blood pressure, mm Hg
Baseline 68.9±9.2 70.6±10.3 0.59
3 months 67.4±10.3 69.0±9.6
△ −1.5±9.4 −1.6±12.8 0.97
Heart rate, /m
Baseline 65.4±12.1 70.0±13.5 0.27
3 months 63.9±12.4 72.6±15.5
△ −1.4±7.7 2.6±10.4 0.17
6MWD, m
Baseline 468±78 444±83 0.81
3 months 465±105 454±87‡
△ −3±35 10±23 0.20
MLHFQ score
Baseline 24.3±20.2 28.4±23.2 0.56
3 months 18.8±17.1‡ 23.9±21.5‡
△ −5.4±13.7 −4.5±11.6 0.81
Values are expressed as mean±SD.
ASV, adaptive servoventilation; 6MWD, 6 min walking distance;
MLHFQ, Minnesota Living with Heart Failure Questionnaire.
*p Value for comparison between the ASV and oxygen groups.
†p<0.05 versus baseline within the same group.
‡p<0.10 versus baseline within the same group.
Figure 3 Changes in the plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level from baseline to treatment titration
and 3 months of therapy: full analysis set. Plotted line graphs indicate the mean±SE at each assessment. The changes in
NT-proBNP level throughout the study were compared by one-way and two-way repeated measure analyses of variance with post
hoc pairwise comparison within the same group and between the two groups, respectively, after NT-proBNP values were
log-transformed. *In the adaptive servoventilation group, the plasma NT-proBNP level decreased significantly from baseline to
titration (1535±2224 to 1251±2003 pg/mL, p<0.01). At 3 months, it increased slightly and its change from baseline did not reach
statistical significance (1311±1592 pg/mL, p=0.08). On the other hand, the oxygen group did not show a significant change
throughout the study (baseline 1071±1887, titration 980±1913, follow-up 1101±1888 pg/mL, p=0.19). †The difference in the
change in NT-proBNP throughout the study between the two groups did not reach statistical significance (p=0.30).
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negative effects of ASV. On the other hand, with regard
to resolution of SDB, oxygen therapy showed good adher-
ence and a trend towards improving patient QoL. Since
oxygen therapy did not show a signiﬁcantly worse effect
on cardiac parameters, compared with the baseline con-
dition, it may be an acceptable alternative treatment for
ASV among patients with CHF with SDB.
The limitations of this study should be considered.
First, the number of patients was small and did not reach
the determined goal. Further, since we did not include a
control group with neither ASV nor oxygen therapy, we
could not draw deﬁnite conclusions. To date, however,
this study is the largest RCT comparing the effect of ASV
and oxygen therapy on patients with CHF with SDB, and
the results may be helpful to design future studies.
Second, it was not possible for the attending physicians
or patients to be blind to the therapy. However, since the
sonographer and sleep technicians who scored PSG were
blind to the treatment allocation, observer bias did not
affect the results. Lastly, although we randomly allocated
the treatments, the ASV group had a smaller BMI at base-
line as compared with the oxygen group. Since a higher
BMI is associated with a better prognosis for patients with
CHF,19 20 the ASV group might have included patients
with a worse condition as compared with the oxygen
group, and this difference might have affected the
response to the treatments.
In summary, although ASV suppressed SDB in patients
with CHF more efﬁciently than did oxygen therapy,
cardiac function did not change signiﬁcantly in either
group. Although a deﬁnite conclusion cannot be made
because of the small number of participants, our data
do not seem to support routine use of ASV or oxygen
therapy to improve cardiac function in patients with
CHF with SDB. Given the discrepant results among pre-
vious studies and the present one, further studies identi-
fying patients with CHF who can beneﬁt from SDB
treatments are warranted.
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